MedMira Advances Rapid Diagnostics With Health Canada Approval
HALIFAX, NOVA SCOTIA | December 30, 2025 — MedMira Inc. reported its first-quarter FY2026 results, highlighting a pivotal period...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
HALIFAX, NOVA SCOTIA | December 30, 2025 — MedMira Inc. reported its first-quarter FY2026 results, highlighting a pivotal period...
SALT LAKE CITY, December 29, 2025 — Co-Diagnostics announced that the Australian Patent Office has granted a key patent...
